Cargando…
A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330074/ http://dx.doi.org/10.1186/1750-9378-7-S1-O15 |
| _version_ | 1782229929586327552 |
|---|---|
| author | Deeken, John F Rudek, Michelle A Moore, Page C Aboulafia, David Sullivan, Ryan Gerecitano, John Cianfrocca, Mary Henry, David Ratner, Lee Dezube, Bruce Mosby, Kimberly Tibbals, Melinda Little, Richard F Ivy, S P Mitsuyasu, Ronald T |
| author_facet | Deeken, John F Rudek, Michelle A Moore, Page C Aboulafia, David Sullivan, Ryan Gerecitano, John Cianfrocca, Mary Henry, David Ratner, Lee Dezube, Bruce Mosby, Kimberly Tibbals, Melinda Little, Richard F Ivy, S P Mitsuyasu, Ronald T |
| author_sort | Deeken, John F |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3330074 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2012 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-33300742012-04-20 A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 Deeken, John F Rudek, Michelle A Moore, Page C Aboulafia, David Sullivan, Ryan Gerecitano, John Cianfrocca, Mary Henry, David Ratner, Lee Dezube, Bruce Mosby, Kimberly Tibbals, Melinda Little, Richard F Ivy, S P Mitsuyasu, Ronald T Infect Agent Cancer Oral Presentation BioMed Central 2012-04-19 /pmc/articles/PMC3330074/ http://dx.doi.org/10.1186/1750-9378-7-S1-O15 Text en Copyright ©2012 Deeken et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Oral Presentation Deeken, John F Rudek, Michelle A Moore, Page C Aboulafia, David Sullivan, Ryan Gerecitano, John Cianfrocca, Mary Henry, David Ratner, Lee Dezube, Bruce Mosby, Kimberly Tibbals, Melinda Little, Richard F Ivy, S P Mitsuyasu, Ronald T A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 |
| title | A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 |
| title_full | A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 |
| title_fullStr | A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 |
| title_full_unstemmed | A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 |
| title_short | A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 |
| title_sort | phase 1/pk study of sunitinib with highly active antiretroviral therapy (haart) in hiv+ patients with solid tumors: aids malignancy consortium study 061 |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330074/ http://dx.doi.org/10.1186/1750-9378-7-S1-O15 |
| work_keys_str_mv | AT deekenjohnf aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT rudekmichellea aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT moorepagec aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT aboulafiadavid aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT sullivanryan aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT gerecitanojohn aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT cianfroccamary aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT henrydavid aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT ratnerlee aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT dezubebruce aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT mosbykimberly aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT tibbalsmelinda aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT littlerichardf aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT ivysp aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT mitsuyasuronaldt aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT deekenjohnf phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT rudekmichellea phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT moorepagec phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT aboulafiadavid phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT sullivanryan phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT gerecitanojohn phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT cianfroccamary phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT henrydavid phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT ratnerlee phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT dezubebruce phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT mosbykimberly phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT tibbalsmelinda phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT littlerichardf phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT ivysp phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT mitsuyasuronaldt phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 |